Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 1;26(4):229-233.
doi: 10.34172/aim.2023.35.

Cohort Profile: Shiraz Pediatric Liver Cirrhosis Cohort (SPLCCS)

Nasrin Motazedian  1 , Bita Geramizadeh  1 , Seyed Mohsen Dehghani  1 , Negar Azarpira  1 , Mahdokht Hossein Aghdaei  1 , Ramin Yaghobi  1 , Alireza Shamsaeefar  2 , Kourosh Kazemi  2 , Mohammad Hossein Karimi  1 , Alireza Mirahmadizadeh  3 , Amirali Mashhadiagha  1   4 , Maryam Ataollahi  5 , Homa Ilkhanipoor  5 , Mitra Basiratnia  5 , Hamid Nemati  5 , Maryam Ekramzadeh  6 , Anahita Sanaei Dashti  5 , Saman Nikeghbalian  2 , Seyed Ali Malekhosseini  2
Affiliations

Cohort Profile: Shiraz Pediatric Liver Cirrhosis Cohort (SPLCCS)

Nasrin Motazedian et al. Arch Iran Med. .

Abstract

Liver diseases in children and adolescents are a significant and arising public health issue and should be surveyed from different dimensions (clinical and para-clinical, psychological, socio-economic) and in diverse populations. Shiraz Liver Transplant Center, Shiraz, Iran is the only center for pediatric liver transplantation and its pre-operative evaluations. This provides a unique and valuable situation for studying this vulnerable population. The Shiraz Pediatric Liver Cirrhosis Cohort Study (SPLCCS) was established to assess cirrhotic children, the course of their disease, and treatment over time. This cohort study aimed to prospectively evaluate the natural course and factors that contributed to complications and death of children with chronic liver disease in the region. SPLCCS was launched in September 2018 after obtaining ethical approval; until August 2022, 370 children with end-stage liver disease were enrolled and followed every six months. Here, the cohort's features, the included population's baseline characteristics, and primary outcomes are reported.

Keywords: Adolescent; Child; Liver diseases; Liver transplantation; Longitudinal study; Mortality.

PubMed Disclaimer

Conflict of interest statement

Competing Interests

None declared.

Figures

Figure 1
Figure 1
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Liu Z, Mao X, Jin L, Zhang T, Chen X. Global burden of liver cancer and cirrhosis among children, adolescents, and young adults. Dig Liver Dis. 2020;52(2):240–3. doi: 10.1016/j.dld.2019.11.001. - DOI - PubMed
    1. Della Corte C, Mosca A, Vania A, Alterio A, Alisi A, Nobili V. Pediatric liver diseases: current challenges and future perspectives. Expert Rev Gastroenterol Hepatol. 2016;10(2):255–65. doi: 10.1586/17474124.2016.1129274. - DOI - PubMed
    1. The Lancet Gastroenterology & Hepatology. Series from the Lancet Journals. Paediatric and Adolescent Liver Disease. May 5, 2017. Available from: https://www.thelancet.com/journals/langas/home.
    1. Nielsen J, Christensen VB, Borgwardt L, Rasmussen A, Østrup O, Kjær MS. Prognostic molecular markers in pediatric liver disease - are there any? Biochim Biophys Acta Mol Basis Dis. 2019;1865(3):577–86. doi: 10.1016/j.bbadis.2018.12.018. - DOI - PubMed
    1. Pinto RB, Schneider AC, da Silveira TR. Cirrhosis in children and adolescents: an overview. World J Hepatol. 2015;7(3):392–405. doi: 10.4254/wjh.v7.i3.392. - DOI - PMC - PubMed